ITGAX and systemic lupus erythematosus: The data presented here suggest that IgA2 PBs and, to a lesser extent, CD11c+Tbet+ B cells are two distinct terminally differentiated effector B cell lineages present in patients with lupus that are particularly sensitive to the rise in BAFF levels following rituximab due to their increased BAFFR expression.